AMRX (Amneal Pharmaceuticals) Total Stockholders Equity: $33 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AMRX Amneal Pharmaceuticals Inc AMRX
56 GF Score
Price $18.85
GF Value $8.15
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Amneal Pharmaceuticals Total Stockholders Equity?

Amneal Pharmaceuticals AMRX +2.86% 56 Total Stockholders Equity is $33 Mil as of Jun. 2026. GuruFocus rates AMRX with a GF Score™ of 56/100 and a GF Value™ of $8.15 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Amneal Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $33 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Amneal Pharmaceuticals's Book Value per Share for the quarter that ended in Jun. 2026 was $0.10. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Amneal Pharmaceuticals's Debt-to-Equity for the quarter that ended in Jun. 2026 was 84.54.

Amneal Pharmaceuticals  (NAS:AMRX) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Amneal Pharmaceuticals's Book Value per Share for the quarter that ended in Jun. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(33.024-0)/319.331
=0.10

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Amneal Pharmaceuticals's Debt-to-Equity for the quarter that ended in Jun. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(121.421 + 2670.34) / 33.024
=84.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amneal Pharmaceuticals Total Stockholders Equity Related Terms

Amneal Pharmaceuticals Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Amneal Pharmaceuticals's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amneal Pharmaceuticals Total Stockholders Equity Chart

Amneal Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 360.34 298.42 19.78 -109.27 -70.79

Amneal Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -112.12 -109.46 -70.79 -45.41 33.02
AMRX
56GF Score
Amneal Pharmaceuticals Inc AMRX
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $33 Mil mean?
Amneal Pharmaceuticals (AMRX) has a Total Stockholders Equity of $33 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Amneal Pharmaceuticals and its competitors.
Is Amneal Pharmaceuticals' Total Stockholders Equity too high?
Amneal Pharmaceuticals' current Total Stockholders Equity is $33 Mil. Overall, Amneal Pharmaceuticals has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Amneal Pharmaceuticals' Total Stockholders Equity compare to HIMS and KNSA?
Amneal Pharmaceuticals' Total Stockholders Equity of $33 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Drug Manufacturers company?
A good Total Stockholders Equity depends on the Drug Manufacturers industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Amneal Pharmaceuticals and its competitors. Amneal Pharmaceuticals's current Total Stockholders Equity is $33 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amneal Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amneal Pharmaceuticals (AMRX) is currently considered Significantly Overvalued. The stock's GF Value™ is $8.15, compared to a current price of $18.85 — trading 131.3% above its estimated fair value. The current Total Stockholders Equity is $33 Mil. Amneal Pharmaceuticals' overall GF Score™ is 56/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Amneal Pharmaceuticals (AMRX), the current Total Stockholders Equity is $33 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amneal Pharmaceuticals (AMRX) Overvalued in 2026?

Based on GuruFocus' analysis, Amneal Pharmaceuticals stock appears to be overvalued. The current stock price of $18.85 is trading 131.3% above its estimated GF Value™ of $8.15. GuruFocus considers Amneal Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for AMRX:

  • Total Stockholders Equity: $33 Mil
  • GF Value™: $8.15 vs. price of $18.85 (131.3% above fair value)
  • GF Score™: 56/100 with 7 warning signs

No single metric tells the full story. See the AMRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Amneal Pharmaceuticals Business Description

Other Exchanges 2DT:Germany
Address 400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ, USA, 08807
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
56GF Score

Get the complete analysis for AMRX

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.85
Price
$8.15
GF Value